OPEN LETTER

REVISED **COVID-19 and the HIV care continuum in Uganda: minimising collateral damage [version 2; peer review: 1 approved, 1 approved with reservations]**

Enock Kagimu ¹, Emily M. Martyn ^{1,2}, Jane Gakuru¹, John Kasibante¹, Morris K Rutakingirwa ¹, Richard Kwizera ¹, Kenneth Ssebambulidde¹, Darlisha Williams^{1,3}, Jayne Ellis^{1,4}, Fiona V Cresswell ^{1,4,5}, David B. Meya¹

¹Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda

²North Middlesex University Hospital, London, UK, London, UK

³University of Minnesota, MN, USA, minneapolis, MINNESOTA, USA

⁴London School of Hygiene and Tropical Medicine, London, UK

⁵MRC-UVRI-LSHTM Uganda Research Unit, Entebbe, Uganda

v2 First published: 02 Jul 2020, 3:28
<https://doi.org/10.12688/aasopenres.13099.1>
 Latest published: 24 Mar 2021, 3:28
<https://doi.org/10.12688/aasopenres.13099.2>

Abstract

The novel coronavirus, SARS-CoV-2, has spread across the world within months of its first description in Wuhan, China in December 2019, resulting in an unprecedented global health emergency. Whilst Europe and North America are the current epicentres of infection, the global health community are preparing for the potential effects of this new disease on the African continent. Modelling studies predict that factors such as youthful and rural population may be protective in mitigating the spread of COVID-19 in the World Health Organisation (WHO) African Region, however, with 220 million infections and 4.6 million hospitalisations predicted in the first year of the pandemic alone, fragile health systems could still be placed under significant strain. Furthermore, subsequent disruptions to the provision of services for people living with HIV, or at risk of acquiring HIV, are predicted to lead to an extra 500,000 adult HIV deaths and a 2-fold increase in mother to child transmission of HIV in sub-Saharan Africa in 2020-2021. Ignoring these predictions may have severe consequences and we risk “stepping back in time” in AIDS-related deaths to numbers seen over a decade ago. Reflecting on our current experience of the COVID-19 pandemic in Uganda, we explore the potential impact of public health measures implemented to mitigate spread of COVID-19 on the HIV care continuum, and suggest areas of focus for HIV services, policy makers and governments to urgently address in order to minimise the collateral damage.

Open Peer Review

Approval Status ? ✓

	1	2
version 2 (revision) 24 Mar 2021		✓ view
version 1 02 Jul 2020	? view	? view

1. **Tolulope Tokunoyori Oladele** , National Agency for the Control of AIDS (NACA), Abuja, Nigeria
2. **Kristen D. Krause**, Rutgers School of Public Health, Newark, USA

Any reports and responses or comments on the article can be found at the end of the article.

Keywords

COVID-19, HIV care, PLWHIV, Opportunistic infections, sub-Saharan Africa

This article is included in the [Coronavirus \(COVID-19\)](#) collection.

Corresponding author: Enock Kagimu (kanockenock@gmail.com)

Author roles: **Kagimu E:** Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Martyn EM:** Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Gakuru J:** Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Kasibante J:** Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Rutakingirwa MK:** Writing – Review & Editing; **Kwizera R:** Writing – Review & Editing; **Ssebambulidde K:** Writing – Review & Editing; **Williams D:** Writing – Review & Editing; **Ellis J:** Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Cresswell FV:** Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Meya DB:** Supervision, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: This work was supported by the African Academy of Sciences (AAS) through the Training Health Researchers into Vocational Excellence in East Africa-2 (THRIVE-2) programme, through grants award to DM and RK, of the Developing Excellence in Leadership, Training and Science in Africa (DELTAS Africa) initiative [DEL-15-011 and DEL-15-130]. The DELTAS Africa Initiative is an independent funding scheme of the AAS's Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust [107742/Z/15/Z] and the UK government.

Copyright: © 2021 Kagimu E *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Kagimu E, Martyn EM, Gakuru J *et al.* **COVID-19 and the HIV care continuum in Uganda: minimising collateral damage [version 2; peer review: 1 approved, 1 approved with reservations]** AAS Open Research 2021, 3:28 <https://doi.org/10.12688/aasopenres.13099.2>

First published: 02 Jul 2020, 3:28 <https://doi.org/10.12688/aasopenres.13099.1>

REVISED Amendments from Version 1**Abstract:**

Article "a" has been removed from "a youthful and rural population"

Introduction:

Covid confirmed cases and deaths updated to current global figures.

Article "a" added to "younger and more rural population", "Though the article makes reference to the fact that Uganda may have successfully curbed the spread of COVID-19, there is limited evidence such as delayed community transmission, limited number of cases, reducing new infections to support the statement " was added.

Covid 19 challenges and HIV care continuum in Uganda:

PLWHIV changed to PLHIV (People living with HIV) throughout the paper, "and instituted control measures" added to sentence in paragraph 2.

"Global lockdowns and travel restrictions threaten manufacture and supply, particularly to tenofovir-lamivudine-efavirenz and tenofovir-lamivudine-dolutegravir, which is first line therapy for an estimated 80% of PLHIV in low- and middle-income countries. Lopinivir and ritonavir global supply was also particularly threatened, given initial interest in its use as an experimental therapeutic agent for COVID-19" added to bring out interruption in ART supply chain

Respective references added.

Improved epidemic preparedness:

In the last 5 months updated to "last 1 year"

Any further responses from the reviewers can be found at the end of the article

Introduction

Coronavirus disease 2019 (COVID-19), caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first described in Wuhan, China in December 2019 and to date there have been more than 106,375,662 confirmed cases, with at least 2,321,294 deaths, globally¹. Recent modelling studies predict fewer deaths and severe infections in Africa compared to the United States and Europe, potentially due to a younger and more rural population. Despite this, it is predicted that within the first year nearly a quarter of Africa's 1 billion population may be infected with the pandemic continuing for a longer period with 4.6 million hospitalisations, which will still pose a significant strain on health systems^{2,3}. Sobering estimates from World Health Organisation (WHO) and UNAIDS suggest a disruption in antiretroviral therapy (ART) due to COVID-19 could lead to more than 500,000 extra deaths from AIDS-related opportunistic infections in sub-Saharan Africa and reverse gains made in preventing mother-to-child transmission of HIV, with an increase in new child infections of up to 104% in Uganda⁴. These figures were described by Dr Tedros Adhanom Ghebreyesus, Director-General of the WHO as "stepping back into history"⁵. In this commentary, we present Uganda as an example of a sub-Saharan African country who quickly enacted strict containment measures. Though the article makes reference to the fact that Uganda may have successfully curbed the spread of

COVID-19, there is limited evidence such as delayed community transmission, limited number of cases, reducing new infections to support the statement. The success of these containment measures may result in profound consequences on the HIV care continuum. We suggest globally applicable measures for HIV service providers, government and policy makers to urgently consider in order to minimise the lasting collateral damage to HIV prevention and treatment efforts threatened by this pandemic.

COVID-19 challenges and the HIV Care Continuum in Uganda

Uganda has a population of almost 43 million people including 1.4 million people living with HIV (PLHIV)^{6,7}. Excellent progress has been made towards the UNAIDS "90-90-90" 2020 targets with 84% of the population aware of their HIV status and 87% of these on ART, of which 88% of people are virally suppressed. At its peak in the 1990's, Uganda's HIV prevalence was 18–30%, which was reduced to 5.7% in 2019, largely due to the roll out of antiretroviral therapy (ART) and extensive public health campaigns around the importance of HIV testing, initiating ART and counselling on drug adherence⁷.

The current pandemic and instituted control measures threatens to reverse these accomplishments. As soon as the first case of COVID-19 was identified in Uganda on 19th March 2020, strict lockdown measures were enforced, including a ban on all public and private transport, night curfew, closure of schools, suspension of religious and social gatherings, and closure of non-essential shops and markets⁸. Firstly, these measures present barriers to HIV testing, in particular initiatives for testing Uganda's most vulnerable groups, including workplace testing, mobile mass testing campaigns and self-testing amongst fishermen, sex-workers and male partners of women attending antenatal care⁷. For those with a new diagnosis of HIV, closures of clinics and the practicalities of leaving the house during lockdown prohibit essential linkage to care. However, our gravest concern is the real possibility of substantial ART interruption. Global lockdowns and travel restrictions threaten manufacture and supply, particularly to tenofovir-lamivudine-efavirenz and tenofovir-lamivudine-dolutegravir, which is first line therapy for an estimated 80% of PLHIV in low- and middle-income countries⁹. Lopinivir and ritonavir global supply was also particularly threatened, given initial interest in its use as an experimental therapeutic agent for COVID-19¹⁰. In Uganda, this is likely multifactorial: supply chain issues as borders are closed, the inability of people to leave their homes to obtain essential medications, and people relocating to villages away from their HIV clinics. Additionally, there is the dire situation of poverty and hunger faced by many individuals, where mere survival rather than maintaining HIV care has become the priority. This disruption in ART access has very real consequences on those who were previously adherent to ART and virologically suppressed. Significant lapses in HIV virological suppression may result in increased community transmission of HIV in Uganda and other comparable settings, which would represent a catastrophic downstream effect of COVID-19 (Figure 1).

Figure 1. Challenges posed to the HIV care continuum by the COVID-19 pandemic. COVID-19 -Coronavirus disease (2019), ART- Antiretroviral therapy.

Minimising collateral damage: focus points for HIV service providers, policy makers and Government

We suggest four focus points for HIV service providers, policy makers and governments to minimise collateral damage of the COVID-19 pandemic in Uganda, which are applicable to similar sub-Saharan African countries (Figure 2).

1. Increase in innovative, adaptive, decentralised, community-based care. It is increasingly recognised that successful HIV care depends on adapting to the individual's needs and expectations, especially in a pandemic¹¹. One such measure already recommended by WHO in response to COVID-19 is multi-month ART prescriptions for stable patients¹². However, ongoing maintenance of HIV care will require pro-active steps by HIV services, backed by adequate government funding and donor support. Adaptions to service delivery, such as telemedicine, must be incorporated so that clients can access essential care during prolonged lockdown. Hotlines should be set up in the event of an emergency, providing mobile credit allowance or toll-free numbers. Since less than 50% of the Ugandan population own a mobile phone, there should be provision of simple handsets or access to a shared community phone. For those who have relocated back to rural communities, issuing a universal HIV passport allowing clients to access medication at any clinic would prevent unintentional ART interruption. Ensuring PLHIV have adequate food, water, soap and access to essential concomitant medications such as cotrimoxazole and fluconazole,

are also essential and is something we have prioritised for the most vulnerable clients through donations at the Infectious Disease Institute, Kampala.

2. Increased community engagement. The community of PLHIV, particularly in Uganda, has a strong history of activism and peer support. For example, many HIV services have community advisory boards comprised of patient representatives, religious and community leaders. In these challenging times, existing community networks, social media, radio and television should be leveraged to disseminate important public health messages pertaining to both COVID-19 prevention and HIV care, including HIV testing, ART adherence and encouraging people to access healthcare when needed, even during lockdown periods.

3. Healthcare system strengthening. Uganda has strong vertical health programmes such as HIV, TB and malaria control programmes; however, pandemics quickly expose lack of horizontal integration and a fragile surrounding healthcare infrastructure¹³. COVID-19 will hopefully provide a wake-up call to government, donors and policy makers to invest in strengthening the Ugandan healthcare system so that essential HIV care can be maintained despite increased pressures posed by the pandemic. This should include increased training and retention of nursing, medical and auxiliary healthcare workers, ensuring adequate stock of medications and diagnostic

Figure 2. Suggested solutions to mitigate some of the major impacts of COVID-19 to HIV care and health systems and management of future pandemics. COVID-19 -Coronavirus disease (2019), ART- Antiretroviral therapy, PPE - Personal Protective equipment.

laboratory equipment and provision of increased high-dependency unit beds and oxygen supply within government healthcare facilities, the only healthcare available to most Ugandans.

4. Improved epidemic preparedness. In the last 1 year, epidemic preparedness has become a top priority worldwide. In fact, at this time the global community might consider looking to Uganda's experiences managing infectious epidemics such as HIV, Ebola, and Marburg for lessons in their own COVID-19 responses. Thankfully, COVID-19 spread in the African continent is predicted to be slower than in Europe and the United States, giving governments some time to prepare their responses². Nevertheless, ongoing efforts are required to upscale testing and contact tracing, rapidly train and mobilise a COVID-19 workforce, source adequate personal protective equipment (PPE) and ensure adequate access to adequate clean water, soap, and sanitizers for both healthcare facilities and the general population. In addition, emphasis should be placed on mobilisation of funds and streamlined regulatory processes to facilitate context-specific research on the epidemiology and clinical course of COVID-19 in PLHIV, to avoid reliance on research findings being extrapolated from the global North.

Conclusion

Failing to recognise the potential impact of the current pandemic on the HIV care continuum in Uganda, and similar sub-Saharan African countries, could result in a huge upsurge in HIV transmission and deaths in the months and years to come. In addition, increasing global travel, urbanization and changes in land use mean that future pandemics are almost inevitable¹⁴. Substantial action must be taken now by HIV service providers, policy makers and governments in sub-Saharan Africa to create innovative, sustainable and effective solutions to prevent us "stepping back in time" in HIV care and minimise the collateral damage of COVID-19 on the HIV care continuum.

Data availability

Underlying data

No data are associated with this article.

Acknowledgements

We thank the institutional leadership from Drs. Andrew Kambugu, Barbara Castelnovo.

References

1. WHO: **Coronavirus disease (COVID-19) pandemic.** (Accessed 21 May 2020).
[Reference Source](#)
2. Cabore JW, Karamagi H, Kipruto H, *et al.*: **The potential effects of widespread community transmission of SARS-CoV-2 infection in the WHO African Region: a predictive model.** *BMJ Glob Health.* 2020; e002647.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
3. Diop BZ, Ngom M, Biyong CP, *et al.*: **The relatively young and rural population may limit the spread and severity of COVID-19 in Africa: a modelling study.** *BMJ Glob Health.* 2020; 5(5): e002699.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
4. Jewell BL, Mudimu E, Stover J, *et al.*: **Potential effects of disruption to HIV programmes in sub-Saharan Africa caused by COVID-19: results from multiple mathematical models.** *figshare.* Preprint. (accessed 25 May 2020).
[Publisher Full Text](#)
5. WHO: **The cost of inaction: COVID-19-related service disruptions could cause hundreds of thousands of extra deaths from HIV.** (Accessed 25 May 2020).
[Reference Source](#)
6. The World Bank: **The World Bank, Data.** (Accessed 25 May 2020).
[Reference Source](#)
7. Avert: **HIV and AIDS in Uganda.** (Accessed 25 May 2020).
[Reference Source](#)
8. The Independent: **Full list of 34 Ugandan measures to contain COVID-19.**
[Reference Source](#)
9. UNAIDS: **The impact of the COVID-19 response on the supply chain, availability and cost of generic antiretroviral medicines for HIV in low- and middle-income countries.** Accessed 4 February 2021.
[Reference Source](#)
10. PEPFAR: **PEPFAR Technical Guidance in Context of COVID-19 Pandemic.** Accessed 4 February 2021.
[Reference Source](#)
11. Wilkinson L, Grimsrud A: **The time is now: expedited HIV differentiated service delivery during the COVID-19 pandemic.** *J Int AIDS Soc.* 2020; 23(5): e25503.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
12. WHO: **Q&A: HIV, antiretrovirals and COVID-19.** (Accessed 25 May 2020).
[Reference Source](#)
13. Msuya J: **Horizontal and Vertical Delivery of Health Services: What Are The Trade Offs?** (Accessed 25 May 2020).
[Reference Source](#)
14. Madhav N, Oppenheim B, Gallivan M, *et al.*: **Pandemics: Risks, Impacts, and Mitigation.** In: 3rd, Jamison DT, Gelband H, *et al.*. *Disease Control Priorities: Improving Health and Reducing Poverty.* Washington (DC), 2017.
[PubMed Abstract](#) | [Publisher Full Text](#)

Open Peer Review

Current Peer Review Status: ? ✓

Version 2

Reviewer Report 26 March 2021

<https://doi.org/10.21956/aasopenres.14316.r28519>

© 2021 Krause K. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Kristen D. Krause

Center for Health, Identity, Behavior and Prevention Studies (CHIBPS), Rutgers School of Public Health, Newark, NJ, USA

I have no further comments to make at this time. Thank you for the opportunity to re-review.

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: HIV/AIDS, aging, resilience, LGBTQ health disparities, psychosocial stressors, housing instability.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 1

Reviewer Report 16 December 2020

<https://doi.org/10.21956/aasopenres.14198.r28176>

© 2020 Krause K. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Kristen D. Krause

Center for Health, Identity, Behavior and Prevention Studies (CHIBPS), Rutgers School of Public Health, Newark, NJ, USA

Thank you for the opportunity to review this commentary on minimizing the collateral damage of

the HIV care continuum due to COVID-19. The authors present a clear and informative overview of the myriad of challenges (figure 1) and solutions to mitigate the impact (figure 2) of COVID-19. This is a noteworthy contribution to the literature given Uganda's success in almost meeting the UNAIDS 90-90-90 targets. In addition to the comments provided by our colleague, Tolulope Tokunyori Oladele, I have a few minor suggestions that could strengthen this manuscript.

Abstract:

Determine whether the third sentence should be re-worded to say: "Modelling studies predict that factors such as youthful and rural populations may be protective in mitigating the spread of COVID-19 in the World Health Organisation (WHO) African Region...." instead of "a youthful and rural population."

Introduction/Main text:

Similar to the abstract, in the second sentence, I think there population should be plural OR it should read "a younger and more rural population".

1. Increase in innovative, adaptive, decentralised, community based care.

- Are any of these recommendations based on interventions that have been implemented in some capacity in Uganda or anywhere else? If so, it'd be helpful to cite or reference them so readers can easily find the information and resources (e.g. telemedicine in rural settings and HIV passport usage).

This recommendation could be applied throughout other sections where applicable.

Is the rationale for the Open Letter provided in sufficient detail?

Yes

Does the article adequately reference differing views and opinions?

Yes

Are all factual statements correct, and are statements and arguments made adequately supported by citations?

Partly

Is the Open Letter written in accessible language?

Yes

Where applicable, are recommendations and next steps explained clearly for others to follow?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: HIV/AIDS, aging, resilience, LGBTQ health disparities, psychosocial stressors, housing instability.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 07 Feb 2021

Enock Kagimu, Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda

Reviewer 2 (Kristen D. Krause)

We sincerely thank the reviewers for their expert critique and constructive suggestions. We have responded to each comment in turn.

Abstract:

Determine whether the third sentence should be re-worded to say: "Modelling studies predict that factors such as youthful and rural populations may be protective in mitigating the spread of COVID-19 in the World Health Organisation (WHO) African Region...." instead of "a youthful and rural population."

This has been adjusted.

Introduction/Main text:

Similar to the abstract, in the second sentence, I think there population should be plural OR it should read "a younger and more rural population".

Article "a" has been added to the sentence

1. Increase in innovative, adaptive, decentralised, community based care.

- Are any of these recommendations based on interventions that have been implemented in some capacity in Uganda or anywhere else? If so, it'd be helpful to cite or reference them so readers can easily find the information and resources (e.g. telemedicine in rural settings and HIV passport usage).

This recommendation could be applied throughout other sections where applicable.

Thank you for this comment. Yes, some of these recommendations have been tried out in Uganda though not much data captured for good referencing as some are still being tried out where as some are suggestions for better improvement.

Competing Interests: No Competing interests

Reviewer Report 17 August 2020

<https://doi.org/10.21956/aasopenres.14198.r27657>

© 2020 Oladele T. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Tolulope Tokunyori Oladele

Community Prevention and Care Services Department, National Agency for the Control of AIDS (NACA), Abuja, Nigeria

The article highlights the need for a continued focus on HIV despite the ongoing COVID-19. This is to prevent a reversal of gains already achieved in the fight against HIV citing Uganda as an example. A framework describing how this can happen is provided. Four focus point which HIV service providers, managers and government should note is provided. The article is well written, in clear English and easy to understand.

Addressing the following points will improve the quality of the article:

Introduction:

1. The number of cases and deaths should be updated to the most recent figures.
2. The article "a" should come before "younger" in Line "4".
3. Though the article makes reference to the fact that Uganda may have successfully curbed the spread of COVID-19, there is limited evidence such as "*delayed community transmission, limited number of cases, reducing new infections*" to support the statement. These should be included.

COVID-19 challenges and the HIV Care Continuum in Uganda:

1. The more general abbreviation for "people living with HIV is PLHIV", the authors may consider its usage.
2. The phrase "and instituted control measures" should be added" to the statement "the current pandemic threatens to reverse these accomplishments" as it is the lock-down measures such as restriction of movement that have greatly impacted on access to HIV services.
3. The statement on substantial ART interruption should be strengthened by making reference to the possible global shortage of drugs such as" Tenofovir-Lamivudine-Dolutegravir and Lopinavir/ritonavir" - <https://bestlifeonline.com/coronavirus-medicine-shortages/>, https://www.state.gov/wp-content/uploads/2020/06/06.10.2020_PEPFAR-Technical-Guidance-During-COVID.pdf.
4. Secured funding is a critical component of minimizing collateral damage to HIV. The authors should consider bringing out this point separately from **focus point 1** - increase in

innovative, adaptive, decentralized, community-based care.

Is the rationale for the Open Letter provided in sufficient detail?

Yes

Does the article adequately reference differing views and opinions?

Yes

Are all factual statements correct, and are statements and arguments made adequately supported by citations?

Partly

Is the Open Letter written in accessible language?

Yes

Where applicable, are recommendations and next steps explained clearly for others to follow?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: HIV/AIDS, Health Economics, Obstetrics & Gynaecology

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 07 Feb 2021

Enock Kagimu, Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda

Reviewer 1 (Tolulope Tokunoyori Oladele):

We sincerely thank the reviewers for their expert critique and constructive suggestions. We have responded to each comment in turn.

Introduction:

- **The number of cases and deaths should be updated to the most recent figures.**

These have been updated.

- 1. The article "a" should come before "younger" in Line "4".**

Article "a" has been added.

- **Though the article makes reference to the fact that Uganda may have successfully curbed the spread of COVID-19, there is limited evidence such as "**

delayed community transmission, limited number of cases, reducing new infections"
to support the statement. These should be included.

Thank you for the suggestion, this statement has been added.

COVID-19 challenges and the HIV Care Continuum in Uganda:

- **The more general abbreviation for "people living with HIV is PLHIV", the authors may consider its usage.**

This has been changed to PLHIV throughout the paper

- **The phrase " and instituted control measures" should be added" to the statement "the current pandemic threatens to reverse these accomplishments" as it is the lock-down measures such as restriction of movement that have greatly impacted on access to HIV services.**

This has been added to that line.

- **The statement on substantial ART interruption should be strengthened by making reference to the possible global shortage of drugs such as" Tenofovir-Lamivudine-Dolutegravir and Lopinavir/ritonavir" -**
<https://bestlifeonline.com/coronavirus-medicine-shortages/>,
https://www.state.gov/wp-content/uploads/2020/06/06.10.2020_PEPFAR-Technical-Guidance-During-COVID.pdf.

Thank you for the suggestion, this has been expounded and a reference to this added.

- **Secured funding is a critical component of minimizing collateral damage to HIV. The authors should consider bringing out this point separately from focus point 1 - increase in innovative, adaptive, decentralized, community-based care.**

Thank you our dear reviewer, the point of secured funding has been noted in the epidemic preparedness section.

Competing Interests: No competing interests